• The online advertising ecosystem is transforming as governments worldwide ramp up regulations to rein in collection of consumers’ personal data
• Google’s Privacy Sandbox works toward the end of third-party cookies in Chrome, giving rise to a whole new privacy-compliant identity ecosystem
• As a company driven by the evolution of data privacy and its impact on consumers and companies, Reklaim appears well-positioned to capitalize on emerging market opportunities amid a paradigm shift happening with new privacy laws

User privacy is taking the online space by storm as consumers become increasingly conscious about how their online data is harvested and used. As a result, the online advertising architecture is about to transform, and companies like Reklaim (TSX.V: MYID) (OTCQB: MYIDF) appear ready to seize the market opportunity that emerges amid intensified regulatory and consumer data protection scrutiny.

As consumers increase their presence in the digital space, the data they generate presents both an opportunity for brands to enhance their engagement with target audiences and a responsibility to keep that data safe. In a post-Cambridge Analytica world – a high-profile case exposing how Facebook used personal data from millions of profiles without their consent – consumers are increasingly wary about what data they share and with whom. According to Pew Research, an overwhelming majority of them – 72% – think their online activity is constantly tracked (https://ibn.fm/6AlKv).

Consumers seem to be constantly reminded that their heightened distrust may not be all that unwarranted as the lineup of companies coming into the spotlight due to their data protection failures expands. Most recently, it was Chegg Inc., an EdTech company providing services for high school and college students.

In its commitment to better protect Americans’ privacy and clamp down on businesses that collect personal information without consumers’ complete understanding, The Federal Trade Commission recently announced that it is taking action against Chegg Inc. for its lenient data security practices that exposed personal information about millions of its customers and employees, including, email addresses, passwords and Social Security numbers (https://ibn.fm/GE3H4).

Still, businesses and their digital marketing rely on collecting data on the online behavior of their target audiences. As a result, the sector has been on a winning streak (with revenue exploding at a record 35.4% in 2021) and is gearing up for another watershed year (https://ibn.fm/eOA4i). Without the free rein to collect consumers’ data, digital advertising needs a paradigm shift aligned with the new world in which consumers, regulators and technology companies require improved data privacy standards, which means the end of third-party cookies.

Previously, businesses could track consumers as they moved across multiple platforms and apps, collecting troves of information about their browsing habits. For example, Facebook aggregates a vast amount of data its users share about themselves as they engage with content and their connections. This information was then distributed to businesses that advertise on the platform so that they could deliver more relevant offers to their target audiences. With a bit of tech help called cookies – a piece of code stored in users’ browsers that collects data about them as they visit and interact with the web – businesses were able to learn about consumers’ online behavior. However, as it turns out, not all cookies are created equal. First-party cookies are limited to a single website, platform or app. Third-party cookies are designed to track users across the online space, allowing third parties to follow the entirety of a user’s internet activity and their online behavior and habits across practically the entire digital space.

It’s the third-party cookies that the latest privacy regulation aims to crack down on, and major tech companies play an essential role in these privacy-driven efforts. To protect users’ online privacy and help companies build thriving digital businesses, Google created Privacy Sandbox, a collaborative effort of the web community to develop privacy-first alternatives to third-party cookies. “Stage 1” of the transition will begin in late 2022, while support for third-party cookies is expected to be removed from Google’s Chrome browser in late 2023.

In a cookie-less reality, brands need to rethink their marketing approach and build advertising strategies around alternatives to third-party cookies. The new strategy relies on migration toward a zero- and first-party data approach, which presents a significant opportunity for innovation that allows businesses to mitigate regulatory risk while protecting and growing marketing revenue. This can improve customer satisfaction and enable marketers to make smarter decisions by reducing data silos (https://ibn.fm/mhInK).

Reklaim intends to step in as a company driven by the evolution of privacy and how it impacts consumers and businesses. Founded in 2018 and with headquarters in New York and offices in Toronto, Reklaim offers a privacy-compliant identity ecosystem. The company is focused on selling compliant, zero-party data to Fortune 500 brands and agencies that buy advertising, as well as platforms and data companies that sell data. Reklaim not only helps clients stay compliant amid the rapidly changing privacy market but also gives consumers visibility regarding how their data is collected and compensates them for its use. Positioned for the cookie-less future that is fast approaching, Reklaim seeks to empower consumers to take back control of their digital data that has been collected and sold for years without their explicit consent.

For more information, visit the company’s website at www.ReklaimYours.com.

NOTE TO INVESTORS: The latest news and updates relating to MYIDF are available in the company’s newsroom at https://ibn.fm/MYIDF

• Lexaria Bioscience recently received Independent Review Board approval for its upcoming human clinical nicotine study, NIC-H22-1, and expects to begin dosing soon
• The company hopes to evidence that processing purified nicotine with its patented DehydraTECH(TM) drug delivery technology leads to better oral-tissue absorption and reduced negative experiences compared to leading brands currently available on the market, On! and Zyn
• Last year, Lexaria conducted an animal study evaluating oral nicotine absorption, NIC-A21-1, in which it evidenced that its DehydraTECH technology was ten to twenty times faster in delivering comparable levels of nicotine into the bloodstream than the peak of the concentration-matched controls

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced it had received Independent Review Board (“IRB”) approval for its planned human clinical nicotine study, NIC-H22-1 (https://ibn.fm/ONgsR). According to U.S. Food and Drug Administration (“FDA”) regulations, the receipt of the IRB approval by Lexaria means the company has taken the necessary steps to protect the rights and welfare of humans participating as subjects in its upcoming human study (https://ibn.fm/CQIHx). The pharmacokinetic (“PK”) randomized, double-blinded, cross-over study will comprise 36 human subjects who are current cigarette smokers. Each subject will visit the laboratory, where they will be dosed three times over a period of weeks. Only one of three nicotine pouch brands – DehydraTECH(TM)-nicotine, On! brand manufactured by Altria, or Zyn brand manufactured by Swedish Match – will be administered during each visit. Subjective and objective evaluations will then follow. Through predetermined questionnaires, which will be used for each nicotine pouch, aiding in subjective evaluation, Lexaria will seek data related to throat burn, user experience, gastrointestinal experience, and more. Additionally, blood samples taken a total of eight times per visit will help in objective evaluations associated with the quantity of nicotine in the blood at various time points. At the same time, vital signs such as respiratory rate, heart rate, blood pressure, and temperature will also be collected. “This is a human clinical study to be conducted in the United States. It uses a DehydraTECH-oral nicotine powder that we have developed… The nicotine powder we will be using is one we already tested in animals last year – we had exceptionally strong results,” said CEO Chris Bunka in an interview with Proactive (https://ibn.fm/G7Tmx). “We believe, right now, that the Lexaria oral nicotine powder is the most advanced of its kind in the world, and we are going head-to-head with two of the top three leading brands of oral nicotine powders today: those manufactured by Swedish Match as well as by Altria. So, we are really excited for the study to commence.” Last October, Lexaria announced “outstanding results” from its NIC-A21-1 study evaluating oral nicotine absorption in animals. The company revealed that DehydraTECH needed only 2 to 4 minutes to deliver nicotine levels in blood plasma comparable to levels achieved at 45 minutes with concentration-matched controls. The results also showed that DehydraTECH-nicotine reached statistically significant peak blood plasma levels up to 10x higher overall than controls while still clearing from blood virtually as quickly as the controls. (https://ibn.fm/PuZTI). “We are extremely pleased with the performance of our latest DehydraTECH-2.0 nicotine oral formulations in this study,” said Chris Bunka at that time. “Our technology was ten to twenty times faster in delivering comparable levels of nicotine into the bloodstream than the peak of the concentration-matched controls and went on to far exceed their total delivery, which should provide much greater consumer satisfaction.” Following receipt of the IRB approval, Lexaria expects to begin human dosing soon, with CEO Chris Bunka hinting during the Proactive interview, published November 3, that dosing will “have been completed in the next month or two and results [released] shortly thereafter.” The company hopes to evidence that processing purified nicotine with its patented DehydraTECH drug delivery technology leads to better oral-tissue absorption and reduced negative experiences compared to the brands currently available on the market. Ultimately, and upon undergoing necessary evaluations, Lexaria hopes to license its technology in the oral pouch product category to offer better nicotine satiety and effectiveness, with the goal of one day rendering cigarette smoking and vaping as obsolete. This would potentially help stop the devastating consequences of cigarette smoking – the practice annually claims more than 480,000 lives in the United States (https://ibn.fm/kVjtw) and over 8 million lives globally (https://ibn.fm/9F3jG). Smoking is also linked to such maladies as cancer (trachea, lung, and bronchus), bronchitis, and coronary heart disease. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• EverGen commenced construction at its Core RNG Expansion Project at Fraser Valley Biogas; project is advancing on schedule and on budget with expected completion in Q1 2023
• Expansion is estimated to double FVB’s capacity to ~160,000 GJ of RNG per year; coupled with new long-term offtake agreement executed in current robust RNG market, it is expected to provide significant boost to company’s revenues and EBITDA
• As Canada’s early mover, EverGen seeks to consolidate assets across the country and leverage its expertise in designing and optimizing resilient facilities; with team that has seen more than a hundred RNG projects, company boasts a distinctive competitive advantage

EverGen Infrastructure (TSX.V: EVGN) (OTCQX: EVGIF), Canada’s Renewable Natural Gas infrastructure platform that helps the fight against climate change and transition to a sustainable future, has announced that the company started construction work at its Core RNG Expansion Project at Fraser Valley Biogas –the Abbotsford, BC facility that combines anaerobic digestion and biogas upgrading to produce RNG. The project broke ground in Q3 2022 and is expected to complete in Q1 2023, when the facility will ramp up RNG production to the expanded capacity (https://ibn.fm/BgUzG). “We are proud of what our team has been able to achieve at FVB to date and pleased to see the project advancing on schedule and on budget,” said Chase Edgelow, CEO of EverGen. “All major mechanical equipment is on track for delivery and costs are within our C$13M-C$15M capital budget. These developments, coupled with the execution of a new long-term offtake agreement in a significantly stronger RNG market, will provide a substantial lift to our revenues and EBITDA.” The initial work is focused on an additional anaerobic digestor and upgrades of the existing feedstock processing system with a view to increase the facility’s production capacity. Upon the completion of this expansion project, the new RNG production volumes are expected to double the capacity of the facility to produce ~160,000 GJ of RNG per year. Established in 2011, Fraser Valley Biogas is Canada’s first agricultural digester to produce renewable natural gas. The RNG generated through this project that EverGen acquired in early 2021 is part of FortisBC’s program to supply renewable gas to homes and businesses. Fraser Valley Biogas also provides Abbotsford farms with renewable fertilizer via the digestate produced as part of the process (https://ibn.fm/BC9Z8). As an established independent renewable energy producer focused on acquiring, developing, owning and operating a portfolio of RNG waste-to-energy, and related infrastructure projects, EverGen is confident that it is heading to a catalyst-rich quarter. “We’re one of the first movers in Canada in terms of consolidating assets across the country. I think when we look at the RNG space today, it’s very similar to what the wind and solar space looked like, maybe ten or fifteen years ago. There’s a number of single project owners that are smaller businesses with greenfield projects. There are some existing assets that probably need more capital to be invested. We’ve taken an approach that we want to be a developer developing new projects from scratch, an owner and an operator of these facilities and to have a platform to be able to be in multiple provinces to share resources. That’s been our strategy and we’ve been effectively growing at a rapid pace with acquisitions that we’ve done in BC. This year we’ve done additional acquisitions in Alberta. We’ve got a significant development project, project Radius, the facilities in Ontario that give us our next leg of growth. We are looking at other provinces for other development projects that sit within our pipeline”, said Chase Edgelow describing the company’s growth plans (https://ibn.fm/ErAn8). “It’s about having technical expertise in the RNG space, so having the personnel that understands how to optimize these facilities, how to ensure you’re designing a facility that will be resilient. Our team has seen over a hundred projects in the space and that really helps us have an advantage with some of the smaller asset owners to be able to bring these projects into our portfolio to share the upside with them and to be able to continue to develop and grow across the country,” he concluded as he described the competitive advantage of the company that seeks to position itself as a leader in the RNG market. For more information, visit the company’s website at www.EverGenInfra.com. NOTE TO INVESTORS: The latest news and updates relating to EVGIF are available in the company’s newsroom at https://ibn.fm/EVGIF

• CNS Pharmaceuticals CEO John Climaco participated in 5K run on November 5, to show support for brain tumor patients worldwide and help raise funds for research
• The company recently announced European clinical trial site activations for its potentially pivotal global trial evaluating Berubicin for the treatment of recurring glioblastoma multiforme
• The pivotal trial will study Berubicin’s results compared to the current study of care, Lomustine
• Global brain tumor treatment market was valued at $2,946 million in 2022 and is expected to grow to $5,904 million by 2032

Brain and other central nervous system cancers (“CNS”) represent 1.3% of all new cancer cases in the United States. In 2022, Cancer.gov estimates that there will be 25,050 new cases of brain and CNS cancers, with 18,280 patients dying from the disease (https://ibn.fm/JG0QS). To help raise awareness of these statistics, CNS Pharmaceuticals (NASDAQ: CNSP), a clinical stage biotechnology company specializing in the development of novel treatments for brain tumors, announced that CEO John Climaco participated in The American Brain Tumor Association’s Breakthrough for Brain Tumors(R) 5K Run on November 5, 2022, in Los Angeles, California. “The unmet need in brain tumor treatment is immense and knows no geographic borders. As CEO of CNS, I have come to know many brain tumor patients personally, and the optimism and strength with which they have all faced this terrible diagnosis is a continuing source of inspiration to me,” Climaco commenting, underlining that supporting these patients, their journey, and challenges is both a priority and the core purpose of his company (https://ibn.fm/98YAN). “Across the globe, there is an urgent need for safe and effective GBM treatment options, and I am proud to participate in the BT5K to support the mission of the ABTA, to help bring hope to patients and families, and to raise much-needed funds for research.” The Breakthrough for Brain Tumors(R) 5K Run took place in Hahamongna Watershed Park in Pasadena and will help The American Brain Tumor Association to create and provide patient and caregiver-focused programs throughout the year. These include patient and family meetings, the annual National Conference, and continuing to explore new programs and relationships in the area. Climaco was the single largest fundraiser for the event by raising nearly $5,000 and also placed 7th in his first-ever 5K race. More information the 5K can be found at https://ibn.fm/rfhM4. NetworkNewsAudio (“NNA”), which delivers additional visibility, recognition, and brand awareness in the investment community via distribution to thousands of syndications, recently featured CNS Pharmaceuticals’ recent announcement highlighting the activation of European clinical trial sites for its potentially pivotal global trial evaluating Berubicin for the treatment of recurring glioblastoma multiforme (“GBM”). GBM is one of the most aggressive types of brain cancer, and Berubicin is the first anthracycline to appear to cross the blood-brain barrier. The results from this pivotal trial will compare Berubicin to a current standard of care, Lomustine, with a 2 to 1 randomization of patients to receive either Berubicin or Lomustine (https://ibn.fm/7ZWYY). The global brain tumor treatment market was valued at $2,946 million in 2022. This value is expected to grow at a CAGR of 7.2% over the forecast period, resulting in a valuation of $5,904 million by 2032. Medication advancements and the efficiency of treatments are expected to be a driving factor for growth within the industry – with more pharmaceutical R&D spending also expected (https://ibn.fm/ZecMG). CNS has been granted FDA Fast Track Designation for Berubicin, enabling more frequent interactions with the FDA for guidance on expediting the development and review process. The company has also received an Orphan Drug Designation, which may provide seven years of marketing exclusivity upon approval of an NDA. For more information, visit the company’s website at www.CNSPharma.com. NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• Arizona Metals owns 100% of two copper and gold exploration projects in mining-friendly Arizona
• Both projects have excellent infrastructure, including roads, available power and water access
• Only 3% of the prospectively mineralized trend that hosts the high-grade Kay Mine Deposit has been drilled
• The company had $60 million in cash as of June 30, 2022, to complete Phase 2 and begin Phase 3 drilling at the Kay Mine

Arizona Metals (TSX: AMC) (OTCQX: AZMCF) is a mineral exploration company engaged in advancing precious and base metal deposits in the state of Arizona. Its flagship copper-gold-zinc-silver asset is the Kay Mine Project, located in Yavapai County. The company also owns Sugarloaf Peak gold project in La Paz County. The company in October 2022 received permit approval from the Bureau of Land Management (“BLM”) for two new drill pads, located approximately 1,200 meters west of the Kay Mine Deposit. These new pads will allow for testing of the company’s Western Target, while also allowing for drilling of additional coincident anomalies located between the Central and Western Targets. Construction of the drill road for the Central Target (located 500 meters west of the Kay Mine Deposit) is currently underway, with drilling expected to begin in November 2022. Road construction for the Western Target will begin upon confirmation of BLM acceptance of the company’s posted bond, with drilling expected to commence in Q1 2023. The company is fully funded, with $60 million in cash as of June 30, 2022, to complete the remaining 18,000 meters planned for the Phase 2 program at Kay, as well as an additional 76,000 meters in the Phase 3 program (budgeted at $27 million), which will be used to test the numerous parallel targets heading west of the Kay Deposit, as well as the northern and southern extensions of the Kay Deposit. Arizona Metals Corp. is based in Toronto, Canada. Projects Arizona Metals Corp. owns 100% of the Kay Mine property in Yavapai County, which is located on a combination of patented and BLM claims totaling 1,300 acres that are not subject to any royalties. An historic estimate by Exxon Minerals in 1982 reported a “proven and probable reserve of 6.4 million short tons at a grade of 2.2% copper, 2.8 grams per ton gold, 3.03% zinc, and 55 grams per ton silver.” The historic estimate has not been verified as a current mineral resource. None of the key assumptions, parameters, and methods used to prepare the historic estimate were reported by Exxon, and no resource categories were used. Significant data compilation, re-drilling and data verification may be required by a “qualified person” (as defined in National Instrument 43-101 – Standards of Disclosure for Mineral Projects) before the historic estimate can be verified and upgraded to be a current mineral resource. A qualified person has not done sufficient work to classify it as a current mineral resource, and Arizona Metals is not treating the historic estimate as a current mineral resource. The company also owns 100% of the Sugarloaf Peak Property in La Paz County, which is located on 4,400 acres of BLM claims. Sugarloaf is a heap-leach, open-pit target and has a historic estimate of “100 million tons containing 1.5 million ounces (of) gold” at a grade of 0.5 grams per ton. The historic estimate at the Sugarloaf Peak Property was reported by Westworld Resources in 1983. The historic estimate has not been verified as a current mineral resource. None of the key assumptions, parameters, and methods used to prepare the historic estimate were reported, and no resource categories were used. Significant data compilation, re-drilling and data verification may be required by a qualified person before the historic estimate can be verified and upgraded to a current mineral resource. A qualified person has not done sufficient work to classify it as a current mineral resource, and Arizona Metals is not treating the historic estimate as a current mineral resource. Market Opportunity The World Gold Council, an industry association representing gold producers with hundreds of mining operations in nearly 50 countries around the world, reports that global demand for gold during the first six months of 2022 was 2,189 tons, a 12% increase in demand over the same period in 2021. Demand came primarily from gold bar and coin investors, jewelry consumers, central bank purchases to bolster currency reserves and technology manufacturing. The average price per ounce for the period was $1,871, marking a 1% year-over-year increase. The council reported gold mine production for the period was up 3% over 2021 at 1,764 tons. For the remainder of 2022 and into 2023, the council projects flat gold demand with possible slight increases in gold mine production. The council notes that unpredictable geopolitical factors, the Ukraine war for example, and likelihood of global economic slowdown could have significant near-term impact on gold demand and prices. Management Team Marc Pais is President and CEO of Arizona Metals. He previously founded and served as President of Telegraph Gold (listed as Castle Mountain Mining), which was acquired by Equinox Gold, a TSX-listed mining company. He has seven years of experience as a Mining Analyst, with a focus on precious metals development companies. He holds a B.Sc. in Geological Engineering (Mineral Exploration) from Queen’s University in Canada. David Smith is the Vice President, Exploration of Arizona Metals. He has 30 years of global precious metals exploration experience, including codiscovery of the Solidaridad/La Sabila deposit in Mexico with deposits estimated at 1 million ounces of gold. His core areas of expertise are managing mineral projects from acquisition to exploration, resource modeling and mineral project development. He holds an M.Sc. from the University of Oregon and an MBA from Pinchot University/Presidio Graduate School. Paul Reid is the Executive Chairman of Arizona Metals. He previously founded and served as Executive Chairman of Telegraph Gold (listed as Castle Mountain Mining), which was acquired by Equinox Gold, a TSX-listed mining company. Paul has extensive experience as an Investment Banking professional, involved in raising capital, go-public transactions, and advisory services. For more information, visit the company’s website at www.ArizonaMetalsCorp.com. NOTE TO INVESTORS: The latest news and updates relating to AZMCF are available in the company’s newsroom at https://ibn.fm/AZMCF

• In 2021, a third of the world’s assets under management, including the money of growing numbers of huge public pension funds, were invested according to ESG principles, with the year posting the highest expenditure on ESG initiatives globally
• Correlate recognizes the growing need for businesses to achieve ESG goals and is looking to meet this demand by offering a complete suite of proprietary clean energy assessment solutions, specifically for the commercial real estate industry
• Its unique data-driven approach draws from proprietary analytics, concierge subscription services, and a highly scalable national fulfillment network that has earned it an opportunity pipeline of over $100 million in commercial projects and over $20 million in awarded backlog
• With the cost to hit the UN sustainability goals having risen by 25% over the past year, Correlate is looking to offer an affordable, viable solution, allowing consumers to successfully draw the benefits associated with renewable energy
• The company is also laying the groundwork for the imminent transition to renewable energy by making retrofitting as easy, affordable, and seamless as possible

2021 saw the highest expenditure on Environmental, Social, and Governance (“ESG”) initiatives globally at $649 billion, according to Morningstar Direct. It was further estimated that during that year, a third of the world’s assets under management, including the money of growing numbers of huge public pension funds, were invested according to ESG principles (https://ibn.fm/3r7ES).

The focus on this sector reflected businesses’ acknowledgment of what the planet needs, particularly in the wake of climate change, widening inequality, and other social problems. As businesses continue exploring how to achieve their ESG goals, Correlate Infrastructure Partners (OTCQB: CIPI) offers an affordable and profitable ESG-related energy solution targeted at both companies and organizations.

Correlate, a driver of highly cost-effective energy use optimization solutions, through its two subsidiaries, Correlate and Solar Site Design, offers a complete suite of proprietary clean energy assessment solutions for the commercial real estate industry. It further develops and finances renewable energy projects that allow these investment properties to operate more efficiently from an energy and financial standpoint.

As more companies recognize the significance of ESG goals and achieving them, Correlate is expanding its list of product and service offerings, focusing on renewable solar energy generation, electric vehicle (“EV”) infrastructure, and intelligent efficiency measures. Its unique data-driven approach draws from proprietary analytics, concierge subscription services, and a highly scalable national fulfillment network designed to help building owners profit from fully-funded, turnkey decarbonization and facility health programs.

This approach has earned Correlate an opportunity pipeline of over $100 million in commercial projects, with over $20 million in awarded backlog, a clear indication of how well-received its ESG solutions are by the target market.

With the cost to hit the United Nations (“UN”) sustainability goals having risen by 25% to $176 trillion over the past year, there is a growing need to make ESG-related systems and infrastructure accessible and affordable by the masses. Furthermore, rising economic pressures have also dealt a blow to the progress on several Sustainable Development Goals (“SDGs”), which is further impacting the adoption of ESG measures and infrastructure (https://ibn.fm/HKVBj).

Correlate recognizes the challenge and is out to offer a viable solution targeted toward business owners, companies, and even real estate owners. The company is confident that with its approach, more consumers will adopt renewable energy and even draw the benefits associated with it, both in the short-term and the long term.

Correlate is also laying the groundwork for the imminent transition towards renewable energy in the United States and globally. It is making retrofitting as easy, affordable, and seamless as possible, and by doing so, it is allowing more businesses to shift to renewable energy sources and achieve their ESG goals. It is also proving instrumental in highlighting the value of ESG and the importance of renewable energy in achieving associated ESG goals.

For company information, visit the company’s website at www.CorrelateInfra.com, including the following:

• Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income: www.CorrelateInfra.com/our-process
• Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals: www.CorrelateInfra.com/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

• Coyuchi is currently accepting investments under its Regulation A+ offering and is approaching the $1 million milestone
• KingsCrowd has published a review on Coyuchi, highlighting the company’s strengths and future industry challenges to be met
• The report discusses how few individuals are better suited to run a sustainable company than CEO Eileen Mockus, given her background in working in the sustainable fabrics industry
• Research shows that more consumers are drawn to products that offer sustainability, and will pay more for those products over name brands

Coyuchi, an organic luxury bed, bath, and apparel company setting the gold standard for sustainably produced luxury home goods, is pleased to announce that KingsCrowd, an investor analyst news publication for startup investing, has published a review on the company. The report focuses on Coyuchi’s strengths and the journey necessary for the company to reach unicorn status to provide decent returns to its investors under its Regulation A+ offering. In the KingsCrowd report, titled Coyuchi Is Sewing Sustainability Into Home Goods; author Francis Vu points out that consumers across the board are trying to shop and live more sustainably – and since inception, Coyuchi has made sustainability a core value in its company. Vu mentions that few individuals are better suited to run a company like Coyuchi than the company’s CEO, Eileen Mockus. Eileen began her career in fabric development at Patagonia, one of the few companies focused on creating sustainable consumer products. She currently sits on the board of the Sustainable Cotton Project and Accelerating Circularity. Coyuchi consumers can return used goods through the company’s “2nd Home Take Back” program, which recycles and renews used Coyuchi linens and cleans, mends, and resells refurbished products. These products are sold for 35% to 40% of the original retail price – any products that cannot be renewed are then recycled and used in the company’s cotton blanket product. The Coyuchi cotton blanket is the company’s first fully circular product that uses 52% recycled Coyuchi cotton and 48% new material. Visible growth over the company’s 30-year history is attributed to its simple yet effective approach – producing high-quality, sustainable products using strong branding strategies. Since Eileen took over the company, Coyuchi has seen an annual growth rate of 42%, which will help as it pursues expansion into brick-and-mortar business avenues in the future. Vu’s review of the company presents mixed feelings as Coyuchi moves forward, not only with expansion efforts but as it takes on new investors through its Regulation A+ offering. Retailers find that more consumers are looking for sustainable products, yet very few retailers answer this call. Across all generations, consumers are willing to pay more for sustainable products over brand names. As Gen Z’s consumer influence continues to grow, the necessity for more sustainable product selections grows along with it. This trend will only continue to increase as the younger Gen Z members enter adulthood, outnumbering Gen X and Baby Boomer populations. By 2030, Gen Z will represent 27% of the world’s income, surpassing Millennials by 2031 (https://ibn.fm/rkHbf). KingsCrowd aggregates, analyzes, and rates mission-driven startups raising on the online private markets so that you can invest like a venture capitalist. It provides trusted insights, analytics, and ratings to help you navigate the fragmented market of startup investing and vet the best deals worth adding to your investment portfolio. The full report is available now and can be viewed online with registration and a viewer upgrade (https://ibn.fm/w8TEQ). Also, see link to free upgrade trial: https://ibn.fm/9vdnC For more information, visit the company’s website at www.Coyuchi.com. NOTE TO INVESTORS: The latest news and updates relating to Coyuchi are available in the company’s newsroom at https://ibn.fm/COYU

• Vision Energy in October 2022 announced it had completed conceptual layouts for its Green Energy Hub project in Vlissingen, the Netherlands
• The company in September 2022 announced its commitment to an additional 5.19 acres, expanding its Green Energy Hub project footprint to a total of 40.53 acres
• Vision Energy is on schedule to file for the remaining construction and environmental permits for its Green Energy Hub project by December 2022
• Current hydrogen demand projections for northwest Europe outstrip scheduled production for the next five to 10 years

Vision Energy (OTCQB: VIHDD) (“Vision Energy”) is a forward-looking energy company developing carbon reduced solutions for the commercial, industrial and transportation sectors. Vision Energy is leveraging its team’s proven track-record in site and asset procurement, accelerating development and permitting processes, plant design, and grid integration to facilitate low-carbon energy production, supply and distribution. The company is pursuing reliable offtake relationships and operating partnerships with energy industry participants and end users seeking carbon abatements across feedstock and fuels. Vision Energy is committed to providing low carbon energy solutions with maximized yield, with projects designed to exploit existing gas and power infrastructure, to integrate and facilitate import and/or distribution of reduced-carbon energy to domestic and global supply chains. The company believes that hydrogen and liquid carriers of hydrogen are the most reliable alternatives to fossil fuels. Hydrogen is anticipated by many energy analysts to become more widely competitive as an alternative mobile energy source as early as 2030, as economies of scale drive down costs. According to the International Energy Agency report ‘Hydrogen in North-Western Europe (2021)’, the region is well placed to lead hydrogen adoption as a clean energy source. Today, this region comprises approximately 5% of global hydrogen demand and 60% of European demand. Moreover, the region is home to the largest industrial ports in Europe, where much of this hydrogen demand is located, and presents a well-developed natural gas infrastructure connecting these ports with other industrial hubs. This gas network could be partially repurposed to facilitate hydrogen delivery from production sites to demand centers. Governments in this region also have ambitious goals for greenhouse gas emissions reduction and there is strong political interest in hydrogen as a pathway to maintaining industrial activity in the region. Vision Energy is based in Jersey City, New Jersey. Projects Through wholly owned subsidiary Evolution Terminals BV, Vision Energy is pioneering a Green Energy Hub development project for the import, storage and distribution of low-carbon renewable fuels and hydrogen carriers, strategically located in the North Sea port of Vlissingen at the mouth of the Westerschelde estuary in the Netherlands. This Green Energy Hub is positioned to be the first terminal in Europe focused on green and low-carbon energy products. Vision Energy is at an advanced stage of planning for the construction of its Green Energy Hub and is on schedule to file for the remaining construction and environmental permits by December 2022. The Green Energy Hub design is capable of receiving seagoing vessels, barges and coasters, served by a dedicated deep-water jetty as well as rail and truck loading infrastructure that will enable direct access to purpose-built storage and handling facilities for low-carbon fuels and hydrogen carriers, including ammonia, methanol and liquid organics. Phase 1 capital expense is estimated at approximately €450 million, including jetty infrastructure, and will provide for up to 400,000 cubic meters (“CBM”) of storage capacity with land already secured for future expansion. Market Opportunity In Northwestern Europe, the market for green hydrogen, or hydrogen produced by renewable energy, is growing rapidly. The current hydrogen demand projections outstrip the scheduled production for the next five to 10 years. The company believes that all producers will face high demand. Moving beyond its initial Green Energy Hub, Vision Energy is focused on countries where governments support a regulatory standard that promotes hydrogen production and consumption. Many governments have established various incentives and financial mechanisms to accelerate and promote the use of hydrogen as a renewable energy source. The EU, through its European Green Deal, has set an objective to become climate-neutral by 2050, implying the near total phase-out of fossil fuels in the EU energy system, and many countries are working to put in place subsidy programs for the development of green hydrogen facilities in anticipation of this goal. Vision Energy projects its total addressable market at €10 billion by 2050. Management Team Andrew Hromyk is CEO of Vision Energy. He has supported and operated chemical and energy operations in the Permian Basin, central and south Texas, Arkansas, Alberta and internationally. An active investor, he has been involved with companies developing a diverse range of technologies, from enhanced and conventional hydrocarbon recovery processes to wireless infrastructure. He has participated in numerous industrial and commercial real estate developments. He also has served as a director of several private companies that became publicly traded on Nasdaq, NYSE and TSX. He studied economics at Chaminade University and the University of British Columbia. Arron Smyth is Executive Vice President of Corporate Development at Vision Energy. He has more than 18 years of experience in financial services, investment banking, business leadership and operations in both developed and emerging markets. Since 2018, he has been Managing Director Europe for the First Finance group of companies, developing and supporting the group’s private equity investments and projects, including Evolution Terminals, the Netherlands-based developer of tank terminal and port infrastructure for the bulk storage and handling of clean and sustainable energy products. Matthew Hidalgo is CFO of Vision Energy. He has over 15 years of experience in accounting, operations, finance, corporate restructuring and integrating acquisitions. He is a Managing Partner at Turquino Equity LLC, a private equity investment firm. Formerly, he was the controller and operations manager for the largest subsidiary of WPCS International Incorporated, managing over $30 million in annual revenue. Prior roles included managing accounting functions for several Australian subsidiaries. After graduating from Penn State with a bachelor’s degree in accounting, he began his career at PricewaterhouseCoopers. For more information, visit the company’s website at https://visionenergy.com/. NOTE TO INVESTORS: The latest news and updates relating to VIHDD are available in the company’s newsroom at https://ibn.fm/VIHDD

• Odyssey filed for US and global patent protection on its novel breath-propelled, intranasal brain-drug delivery device that effectively deposits concentrated drug deep into the nasal cavity for the treatment of CNS injury disease or disorder
• The application follows the successful completion of the second Cohort of Odyssey’s Phase I MAD clinical trial, which saw the effective use of the device and a proven safety profile for the company’s concussion pharmaceutical treatment
• Michael Redmond, the company’s CEO, has expressed the company’s pleasure in the functionality of the device, citing how it provides a significant opportunity and advantage for the treatment of neurological conditions
• The patent application bolsters Odyssey’s growing list of medical devices, which currently comprise a CardioMap, a heart monitoring and screening device, as well as Save-A-Life, a handheld choking rescue device

Odyssey Health (OTC: ODYY), a medical enterprise focused on unique, life-saving medical products that offer clinical advantages to unmet clinical needs, just announced filing for the United States and global patent protection on its novel breath-propelled, intranasal brain-drug delivery device. This comes on the heels of the successful completion of the second Cohort of its Phase I Multi-Day Ascending Dosing (“MAD”) clinical trial, which saw the successful use of the device, and a proven safety profile of the company’s concussion pharmaceutical treatment. “Following the completion of this Phase I trial, I am very pleased with the safety profile of our concussion pharmaceutical treatment,” noted Michael Redmond, Odyssey’s CEO. “I’m equally pleased that the intranasal drug/device combination has functioned nicely and has been easy to operate in the clinical setting,” he added (https://ibn.fm/0Gf75). The Nasal Device was designed to create an adequate airflow for depositing concentrated drug deep into the nasal cavity and onto the olfactory region for quick and direct diffusion into the brain to treat central nervous system (“CNS”) injury, disease, or disorder. The concussion drug candidate is designed to be administered within a few minutes of a concussive episode, thereby inducing intracellular steroid receptors in brain cells and activating multiple gene response elements that reduce swelling, oxidative stress, and inflammation in the brain. This, in turn, restores proper blood flow to the brain while also avoiding drug-induced fatigue or cognitive decline associated with the prolonged use of drugs associated with concussion treatment (https://ibn.fm/mHCkO). The patent application bolsters Odyssey’s growing list of medical devices that currently comprise a CardioMap – a heart monitoring and screening device for early detection of coronary artery disease, as well as Save-A-Life- a handheld choking rescue device. Mr. Redmond has expressed the company’s pleasure in the functionality and performance of the Nasal Device, citing how it provides a significant opportunity and advantage for treating neurological conditions. “We were very pleased with the functionality and performance of the Nasal Device during the Phase I study and its administration of Odyssey’s concussion drug. The ability to get drugs for neurological conditions delivered directly into the brain rapidly at effective levels while simultaneously having less concern for side effects is a huge advantage in the development of safe and efficacious treatments,” he noted. “Odyssey’s novel Nasal Device provides that opportunity and advantage,” he added (https://ibn.fm/RBlhR). Odyssey is still identifying Phase II trial sites and structuring the study design with the site’s medical leadership and the Odyssey Medical Advisors. The company looks to make further use of the Nasal Device in this phase of the study, while also building on the success of the previous research as it works towards approval by the U.S. Food and Drug Administration (“FDA”). For more information, visit the company’s website at www.OdysseyHealthInc.com. NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY

• In June 2020, CNS’ lead drug candidate, Berubicin, received Orphan Drug designation from the FDA. In June 2021, it received Fast Track designation following positive results from an extensive clinical study that saw 44% of the patients post a clinical response, with one Durable Complete Response
• With GBM having a survival rate of only 6.8% and an average length of survival of only eight months, Berubicin is showing tremendous potential, and CNS is leading the charge to find a potential treatment option for the disease
• CNS’ management is optimistic about its lead drug candidate and continues to explore the potential treatment of other conditions such as lymphomas, lung and breast cancers

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical stage biotechnology company, recognizes the growing problem of metastatic cancers of the brain and central nervous system. More importantly, it recognizes how few and largely ineffective current solutions are available, ultimately contributing to higher mortality rates and a poor quality of life for victims with such conditions. This understanding led to the introduction of Berubicin, the company’s lead drug candidate aimed at treating Glioblastoma Multiforme (“GBM”), with the potential to also deal with other central nervous system malignancies. In June 2020, Berubicin received Orphan Drug designation from the United States Food and Drug Administration (“FDA”) and Fast Track designation in June 2021. These designations came in the wake of positive results following an extensive clinical study in which 44% of patients showed a clinical response of stable disease or better, with one Durable Complete Response. This was a huge milestone for the industry, particularly since over 10,000 individuals with GBM succumb to the disease annually, given its five-year survival rate of only 6.8%. In addition, the condition has an average length of survival for patients of only eight months (https://ibn.fm/mzJy3). “Against the backdrop of statistics that show the aggressiveness of GBM, CNS is leading the charge to find a potential treatment option for the disease,” notes a recent article (https://ibn.fm/8z75X). CNS’ Berubicin, an anthracycline chemotherapy agent, has appeared to demonstrate, based on limited clinical data, the ability to cross the blood-brain barrier to target tumors directly. This has set it apart from other more mainstream anthracyclines, allowing it to achieve more significant outcomes and a potential solution for patients with GBM and other brain tumors. According to the American Cancer Society, about 25,050 malignant tumors of the brain and spinal code will be diagnosed in the United States in 2022 alone. In addition, the society projects that about 18,280 people will die from brain and spinal cord tumors this year (https://ibn.fm/ldQYJ). Cancer.net further projects that about 4,170 children under the age of 15 will also be diagnosed with a brain or CNS tumor this year in the United States (https://ibn.fm/GYQ57). With such numbers, one would understand why CNS received its Fast Track designation from the FDA. Its research so far is the most promising in treating such conditions. Berubicin could potentially help save thousands of people every year and reduce such conditions as GBM to treatable and manageable ailments. CNS’ management is optimistic about prospects for its lead drug candidate. It continues to explore the potential treatment of other conditions such as lymphomas, lung and breast cancers. The company is also expanding its global presence, having already received clinical approvals in Switzerland, France, and Spain. It expects to utilize the Fast Track designation to build on the studies conducted so far to achieve its organizational goals and offer a viable treatment for patients with GBM. “Our focus and priorities remain on advancing our clinical development program for Berubicin to ultimately bring meaningful treatment to GBM patients, families and clinicians, who currently have extremely limited and often ineffective treatment options,” notes John Climaco, CNS’ Chief Executive officer (“CEO”) (https://ibn.fm/IdOem). For more information, visit the company’s website at www.CNSPharma.com. NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP